Princeton, New Jersey , July 02, 2013 – Sandoz today announced the US launch of metronidazole 1% topical gel, the first generic version of METROGEL® 1%. Metronidazole 1% topical gel is indicated for the topical treatment of inflammatory lesions of rosacea1, a condition that affects an estimated 16 million Americans.2 “This significant launch further expands our […]
– Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose – Exelon Patch first and only transdermal therapy approved to treat all stages of Alzheimer’s – More than five million Americans are living with […]
New Tulsa Cancer Institute Offers Accuray’s Latest Cancer Fighting Technology SUNNYVALE, Calif., June 25, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today that the Tulsa Cancer Institute is the first U.S. center to treat a patient with Accuray’s TomoHDA™ System, the latest and most advanced innovation in the TomoTherapy® product lineage designed to treat the full spectrum of cancer […]
Holzkirchen, Germany, June 24, 2013 – Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen’s Enbrel®). Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global […]
Tokyo, Japan, June 21, 2013 – Sandoz today announces the National Health Insurance price listing and launch in Japan of sodium risedronate tablets 2.5mg/17.5 mg [Sandoz], the generic version of BENET® Tablets / ACTONEL® Tab. Sodium risedronate tablets 2.5mg/17.5 mg are indicated for the treatment of osteoporosis. “Sandoz is proud to launch this important generic medicine, […]
June 19, 2013 – Sandoz is pleased that the European Medicines Agency (EMA) has issued a draft revised guideline on non-clinical and clinical issues in biosimilar product development. Overall, the draft revised guideline demonstrates EMA’s continued worldwide leadership in biosimilar regulations by applying science in a risk-based manner that safeguards patient safety without compromising access to […]
Lancaster General Health Unveils Leading Robotic Radiosurgery System SUNNYVALE, Calif., June 13, 2013 – Accuray Incorporated (Nasdaq: ARAY) announced today that Lancaster General Health in Pennsylvania is the first U.S. center to treat a patient with the CyberKnife® M6™ System, the most advanced robotic radiosurgery system in the world and the latest generation of the […]
Advanced Radiation Treatment Now Available to Cancer Patients in France SUNNYVALE, Calif., June 5, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the first patient has been treated with its new TomoHDA™ System at Centre Oscar Lambret in Lille, France. Building upon the proven TomoTherapy® Hi-Art® and TomoHD™ technologies, the TomoHDA System is a fully-integrated […]
Princeton, New Jersey, May 22, 2013 – Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of candesartan cilexetil tablets, the first generic version of ATACAND®. Candesartan cilexetil tablets are indicated to treat some types of heart failure in adults with left ventricular systolic dysfunction, and hypertension in adults and children […]
Updated ASTRO Model Policy Endorses Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer SUNNYVALE, Calif., May 21, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy (SBRT). […]